High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Biogen (NASDAQ:BIIB) reported stronger-than-expected second-quarter results on Wednesday, with revenue and adjusted earnings exceeding Wall Street forecasts as its expanding portfolio of growth products continued to offset weakness in its legacy multiple sclerosis business. The biotechnology company posted revenue of $2.
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.
Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts’ estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Alzheimer’s drug Leqembi narrowly missed expectations.
Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.
The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.
Investing.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.
Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.
Wall Street analysts handed out surprise upgrades and painful downgrades on Monday, shifting outlooks for companies ranging from a pizza chain to a crypto-adjacent fintech as second-quarter earnings season prepares to kick off against a backdrop of Iran strikes and surging Treasury yields.
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
In early June 2026, Biogen reported that the FDA granted Breakthrough Therapy Designation to its investigational SMA treatment salanersen, while also, alongside UCB, presenting additional positive Phase 3 data for lupus candidate dapirolizumab pegol at the EULAR 2026 Congress. Together, these developments highlight Biogen’s expanding late-stage pipeline in severe neuromuscular and autoimmune diseases, with salanersen’s once-yearly dosing and dapirolizumab pegol’s steroid-sparing potential...
Biogen (BIIB) is back in focus after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, while fresh Phase 3 lupus data with partner UCB highlighted dapirolizumab pegol’s clinical profile. See our latest analysis for Biogen. Biogen’s recent FDA breakthrough designation for salanersen and fresh lupus data arrive as the share price trades at US$196.45, with a 90-day share price return of 6.26% and a 1-year total shareholder return of 50.70%,...
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
